Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.

@article{Koontz2008PreoperativeRA,
  title={Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.},
  author={Bridget F Koontz and Edward F. Miles and Mary Ann D Rubio and John F. Madden and Samuel R Fisher and Richard L. Scher and David M. Brizel},
  journal={Head & neck},
  year={2008},
  volume={30 2},
  pages={262-6}
}
BACKGROUND Angiosarcoma of the face is a vascular tumor with poor local control and short median survival despite standard treatment. Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), which can inhibit tumor growth. It is synergistic with radiotherapy in gastrointestinal malignancies. Given the vascular nature of angiosarcoma and the need for better treatment of this disease, we investigated the concurrent use of bevacizumab with preoperative… CONTINUE READING